A review by cannabinoid researcher Ethan Russo argues that cannabis-based medicines, including THC, CBD, their acidic precursors, and terpenes, offer promising approaches to five neurological conditions that currently lack effective treatments.
Neurologists, neuroscience researchers, medical cannabis advocates and skeptics.
Five neurological conditions examined: intractable epilepsy, brain tumors, Parkinson disease, Alzheimer disease, and TBI/CTE.
What the researchers found
The review presents evidence supporting cannabis-based interventions for intractable epilepsy, brain tumors, Parkinson disease, Alzheimer disease, and traumatic brain injury/CTE. These conditions share some pathological processes that may respond to cannabinoid mechanisms including CB1, CB2, PPARgamma, and 5-HT1A receptor activity.
Why it matters
Neurology has largely been limited to symptomatic treatment of neurodegenerative diseases. This review argues that cannabis compounds may offer something more ambitious: the potential to slow, arrest, or even reverse pathological processes rather than just managing symptoms.
The numbers in context
Five target conditions examined: intractable epilepsy, brain tumors, Parkinson disease, Alzheimer disease, and TBI/CTE. Multiple compounds considered: THC, CBD, THCA, CBDA, and terpenes like caryophyllene.
How the study worked
Narrative review synthesizing basic science and clinical evidence for cannabinoid-based treatments across five neurological conditions, examining multiple cannabis compounds and their mechanisms of action.
What this study cannot tell us
Narrative review by a prominent cannabis medicine advocate. Much of the evidence is preclinical or from small studies. The breadth of conditions covered limits depth of analysis for any single disease.
How to read the evidence
Moderate - comprehensive review by an expert in the field, but much evidence is preclinical and the scope is very broad.
When this study was published
Published in 2018. CBD has since been FDA-approved for epilepsy, and research in the other conditions continues.
The bigger picture
The multi-target nature of cannabis compounds may be an advantage rather than a limitation in treating complex neurological diseases. This "polypharmaceutical" approach contrasts with the single-target model that has dominated drug development.
Questions still open
- Which of these five conditions is closest to having cannabis-based treatments validated in large clinical trials? Can the proposed mechanisms be validated in human studies? Would whole-plant preparations outperform isolated compounds?
Common questions
Can cannabis treat Alzheimer or Parkinson disease?
What cannabis compounds beyond THC and CBD show medical promise?
Read the original research
Cannabis Therapeutics and the Future of Neurology.
Frontiers in integrative neuroscience, 12, 51
Citation
Russo, Ethan B. (2018). Cannabis Therapeutics and the Future of Neurology.. Frontiers in integrative neuroscience, 12, 51. https://doi.org/10.3389/fnint.2018.00051
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk